BMC Genomic Data (Jan 2024)

BRCA 1/2 mutations and risk of uterine cancer: a systematic review and meta-analysis

  • Faezeh Zakerinasab,
  • Qumars Behfar,
  • Reza Parsaee,
  • Reza Hossein Zadeh,
  • Elaheh Foroughi,
  • Amirhesam Amirbeik,
  • Ghazalehsadat Ahmadi

DOI
https://doi.org/10.1186/s12863-024-01189-y
Journal volume & issue
Vol. 25, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Purpose In this study, we aim to investigate the association between BRCA1/2 mutation and uterine cancer incidence. Material and method We systematically searched three databases including PubMed, Scopus, and Google Scholar up to August 2023; and reviewed 23 cohorts and cross-sectional studies to explore the association between BRCA1/2 mutations and uterine cancer incidence. Results This systematic review comprised a total of 21 cohort studies and 2 cross-sectional studies after the screening process. According to meta-analysis the prevalence of the BRCA1/2 gene in patients with uterine cancer was 0.02 (95%CI = [0.01,0.03], P < 0.01, I2 = 94.82%) Conclusions Our meta-analysis investigates a 2% prevalence of BRCA1/2 mutation in patients with uterine cancer. Patients with BRCA1/2 mutations might be more conscious of uterine malignancies.

Keywords